Options Trading for Progyny (PGNY) in the First Week of January 2026
Put Contract Overview: The $20.00 put contract for PGNY has a bid of 15 cents, allowing investors to buy shares at a cost basis of $19.85, which is a 19% discount from the current price of $24.84. There is an 86% chance the contract may expire worthless, offering a potential 0.75% return on cash commitment.
Call Contract Overview: The $30.00 call contract has a bid of 20 cents, and if shares are purchased at $24.84 and the call is sold, it could yield a total return of 21.58% if exercised by January 2026. There is a 79% chance this contract may also expire worthless, providing a 0.81% additional return.
Volatility Insights: The implied volatility for the put contract is 68%, while the call contract has an implied volatility of 56%. The actual trailing twelve-month volatility is calculated at 48%.
YieldBoost Concept: Both the put and call contracts offer potential YieldBoosts, with the put providing a 6.22% annualized return and the call offering a 6.68% annualized return if they expire worthless.
Trade with 70% Backtested Accuracy
Analyst Views on PGNY
About PGNY
About the author
Goldman Sachs Upgrades Enphase Energy to Buy, Raises Target to $45
- Analyst Rating Upgrade: Goldman Sachs analyst Brian Lee upgraded Enphase Energy (NASDAQ:ENPH) from Neutral to Buy and raised the price target from $29 to $45, reflecting confidence in its future growth potential.
- Intel Rating Adjustment: HSBC analyst Frank Lee upgraded Intel (NASDAQ:INTC) from Reduce to Hold and increased the price target from $26 to $50, indicating expectations for improved market performance.
- Progyny Market Performance Improvement: Citizens analyst Constantine Davides upgraded Progyny (NASDAQ:PGNY) from Market Perform to Market Outperform and set a price target of $30, suggesting optimism about its business growth.
- Brinker International Rating Upgrade: Morgan Stanley analyst John Glass upgraded Brinker International (NYSE:EAT) from Equal-Weight to Overweight and raised the price target from $160 to $200, reflecting a positive outlook on its future profitability.
Is Progyny's 85.7% Increase in 2025 Already Reflected in Its Growth Narrative?
Progyny's Stock Performance: Progyny's share price has increased significantly, up 50.2% year-to-date and 85.7% over the past year, driven by a growing focus on fertility benefits and a favorable market for scalable healthcare platforms.
Valuation Insights: Despite the stock's strong performance, Progyny scores only 2 out of 6 on valuation checks, indicating that the market may have already priced in much of the positive news.
Discounted Cash Flow Analysis: A Discounted Cash Flow model suggests that Progyny is undervalued by approximately 62.5%, with an intrinsic value of about $71.04 per share compared to its current trading price.
Price to Earnings Ratio: Progyny's current PE ratio of 40.6x is significantly higher than industry averages, indicating that the stock may be overvalued relative to its fundamentals, as the fair PE ratio is estimated at 26.3x.
